A phase-1 trial of intraperitoneal 5-fluorouracil and oxaliplatin in patients with colorectal cancer and unresectable peritoneal metastasis.
腹腔注射 5-氟尿嘧啶和奥沙利铂治疗结直肠癌和不可切除的腹膜转移患者的 1 期试验。
基本信息
- 批准号:10722263
- 负责人:
- 金额:$ 33.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-12 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AbdomenAddressAnimal ModelBiopsyBloodBlood specimenBone MarrowCarcinomatosisCell TherapyCellsClinical TrialsColorectal CancerCombination Drug TherapyCombined Modality TherapyComprehensive Cancer CenterDiseaseDoseEffector CellEligibility DeterminationFlow CytometryFluorouracilFoundationsGreater sac of peritoneumHyperthermiaImageImmuneImmune checkpoint inhibitorImmunologic StimulationImmunooncologyImmunosuppressionIntravenousKnowledgeLaparoscopyLeadLiverLocal TherapyLungMalignant NeoplasmsMaximum Tolerated DoseMethodsMinorityModalityModernizationMorbidity - disease rateMyeloid CellsNeoplasm MetastasisOhioOncologyOncolytic virusesOutcomePatientsPenetrationPeritonealPeritoneumPharmacologyPhasePhenotypePilot ProjectsRecurrent Malignant NeoplasmResearchResource SharingSafetySiteSystemic TherapyToxic effectTumor DebulkingTumor MarkersUniversitiesUnresectableanti-tumor immune responseantitumor agentcancer recurrencechemotherapycytotoxicitydesignearly phase clinical trialefficacy trialgastrointestinalimmune modulating agentsimmunogenic cell deathimproved outcomeindexingintraperitonealintraperitoneal therapyintravenous administrationmetastatic colorectalneoplastic cellnovelnovel therapeutic interventionoxaliplatinpatient populationperitoneal cancerphase I trialresponsestandard of caresurvival outcomesystemic toxicitytumortumor-immune system interactionsvirtual
项目摘要
SUMMARY
Patients with colorectal cancer (CRC) and peritoneal metastases (PM) have significantly worse outcomes than
metastases to other sites like the lungs or liver. In patients with a limited volume of disease based on an
intraoperatively calculated peritoneal carcinomatosis index (PCI) of less than 20, cytoreductive surgery (CRS)
with hyperthermic intraperitoneal chemoperfusion (HIPEC) may provide a survival benefit. Unfortunately, only a
minority of patients are candidates for CRS+HIPEC, and even in patients that undergo CRS + HIPEC, there is
almost universal cancer recurrence. There is a critical need for novel therapeutic strategies, including
regional delivery of anti-tumor agents in patients with CRC PM.
Although 5-fluorouracil (5FU) and oxaliplatin forms the foundation of intravenous (IV) systemic therapy for
patients with metastatic CRC, poor penetration and efficacy of IV chemotherapy in the peritoneum leads to
much poorer outcomes. In animal models, chemotherapies such as 5FU have higher intra-tumoral
concentrations and longer half-lives when administered directly to the peritoneal cavity compared to IV
administration, making intraperitoneal (IP) chemotherapy an attractive treatment modality. While small pilot
studies of IP 5FU from the 1980s and 90s showed promising efficacy, no systematic trials have been
conducted to assess the feasibility of IP chemotherapy in patients with CRC and unresectable PM, and none
using the modern chemotherapy combination of 5-FU + oxaliplatin. Furthermore, there have been no studies
on the effects of IP 5FU+oxaliplatin on stimulating an anti-tumor immune response.
To address these knowledge gaps, we have designed a phase-1 dose-escalation trial of 5FU and oxaliplatin
administered IP in patients with CRC and PM not eligible for CRS+HIPEC due to PCI > 20. This trial will use
the Bayesian optimal interval design (BOIN) to determine the maximally tolerated dose (MTD), with 6 additional
patients treated at the MTD for additional safety, response, and correlative analyses. Patients will undergo a
diagnostic laparoscopy with tumor biopsy at baseline and again after 4 cycles of IP chemotherapy. PCI is
calculated intraoperatively at each diagnostic laparoscopy. Imaging as per SOC will be performed every 2
cycles, and response assessed by RECIST 1.1. Markers for tumor response and immune phenotype will be
analyzed by spectral flow cytometry on tumor and blood samples. Our central hypothesis is that IP
5FU+oxaliplatin will be safe, lead to direct cytotoxicity, and stimulate anti-tumor immune responses due to
immunogenic cell death. Additionally, local administration of chemotherapy may avoid the systemic
immunosuppressive effects of systemic chemotherapy. If successful, this research will form the foundation of
larger efficacy trials to optimize IP chemotherapy alone or in combination with immune-modulating agents, and
ultimately, offers the potential to improve outcomes for a population of patients with poor survival, limited
treatment options, and significant morbidity using affordable and widely available chemotherapy agents.
总结
结直肠癌(CRC)和腹膜转移(PM)患者的预后显著差于
转移到其他部位,如肺或肝。在基于一个
术中计算的腹膜癌转移指数(PCI)小于20,细胞减灭术(CRS)
与热腹腔内化疗灌注(HIPEC)可以提供生存的好处。不幸的是,只有一个
少数患者是CRS+HIPEC的候选者,即使在接受CRS + HIPEC的患者中,
几乎普遍的癌症复发。迫切需要新的治疗策略,包括
在患有CRC PM的患者中局部递送抗肿瘤剂。
虽然5-氟尿嘧啶(5 FU)和奥沙利铂形成静脉(IV)全身治疗的基础,
对于转移性CRC患者,腹膜中IV化疗的渗透性和有效性差导致
更糟糕的结果。在动物模型中,化学疗法如5 FU具有较高的肿瘤内肿瘤生长。
与IV给药相比,
因此,腹膜内(IP)化疗是一种有吸引力的治疗方式。虽然小飞行员
20世纪80年代和90年代的IP 5 FU研究显示出有希望的疗效,但尚未进行系统性试验。
评估IP化疗在CRC和不可切除PM患者中的可行性,
使用5-FU +奥沙利铂的现代化疗组合。此外,没有任何研究表明,
IP 5 FU+奥沙利铂对刺激抗肿瘤免疫应答的作用。
为了解决这些知识缺口,我们设计了一项5 FU和奥沙利铂的I期剂量递增试验
在患有CRC和PM的患者中施用IP,由于PCI > 20而不适合CRS+HIPEC。这次审判将使用
贝叶斯最优区间设计(BOIN)确定最大耐受剂量(MTD),6个额外的
接受MTD治疗的患者进行额外的安全性、缓解和相关性分析。患者将接受
在基线和4个周期IP化疗后再次进行诊断性腹腔镜检查和肿瘤活检。PCI是
在每次诊断性腹腔镜检查术中计算。根据SOC,将每2次进行成像
周期,并通过RECIST 1.1评估缓解。肿瘤反应和免疫表型的标志物将在
通过光谱流式细胞术对肿瘤和血液样品进行分析。我们的核心假设是,
5 FU+奥沙利铂将是安全的,导致直接的细胞毒性,并刺激抗肿瘤免疫应答,
免疫原性细胞死亡。此外,局部施用化疗可避免全身性化疗。
全身化疗的免疫抑制作用。如果成功,这项研究将为
更大规模的疗效试验,以优化IP化疗单独或与免疫调节剂联合使用,以及
最终,提供了改善生存率低、有限的患者人群结局的潜力。
治疗选择,以及使用负担得起的和广泛可用的化疗剂的显著发病率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alex C. Kim其他文献
Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study.
使用 pH 敏感成像剂 Pegsitacinine 检测细胞减灭手术后残留的腹膜转移瘤:II 期研究的最终结果。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:3.7
- 作者:
Patrick L. Wagner;Edward A. Levine;Alex C. Kim;Perry Shen;N. Fleming;S. Westin;Laurel K Berry;G. Karakousis;J. Tanyi;Madeline T Olson;Brian Madajewski;Brian Ostrander;Kartik Krishnan;Charles M. Balch;David L. Bartlett - 通讯作者:
David L. Bartlett
ASO Visual Abstract: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent—Final Results from a Phase 2 Study
- DOI:
10.1245/s10434-024-15307-8 - 发表时间:
2024-05-09 - 期刊:
- 影响因子:3.500
- 作者:
Patrick Wagner;Edward A. Levine;Alex C. Kim;Perry Shen;Nicole D. Fleming;Shannon N. Westin;Laurel K. Berry;Giorgos C. Karakousis;Janos L. Tanyi;Madeline T. Olson;Brian Madajewski;Brian Ostrander;Kartik Krishnan;Charles M. Balch;David L. Bartlett - 通讯作者:
David L. Bartlett
Defining Colorectal Cancer Cells on a Single Cell Level Reveals LGR5+ Proliferative Stem Cell Expression in Peritoneal Metastasis
- DOI:
10.1245/s10434-024-15783-y - 发表时间:
2024-07-16 - 期刊:
- 影响因子:3.500
- 作者:
Kevin Nee;Linzi Hosohama;Wilson Alobuia;Alex C. Kim;Maheswari Senthil;Oliver S. Eng - 通讯作者:
Oliver S. Eng
ASO Visual Abstract: Disparities in␣Care Access to␣Liver-Directed Therapy Among Medicare Beneficiaries with␣Colorectal Cancer Liver Metastasis
- DOI:
10.1245/s10434-022-12652-4 - 发表时间:
2022-10-11 - 期刊:
- 影响因子:3.500
- 作者:
Christopher T. Aquina;Zachary J. Brown;Joal D. Beane;Aslam Ejaz;Jordan M. Cloyd;Allan Tsung;Mohamed O. Adam;Timothy M. Pawlik;Alex C. Kim - 通讯作者:
Alex C. Kim
Alex C. Kim的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 33.64万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 33.64万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 33.64万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 33.64万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 33.64万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 33.64万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 33.64万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 33.64万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 33.64万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 33.64万 - 项目类别:
Research Grant